Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The bill changes the Clinical Laboratory Improvement Amendments so that the Health Secretary, not the FDA, oversees laboratory‑developed tests. It adds clear definitions for terms such as analytical validity, clinical use, and digital laboratory data, and requires that these tests have reasonable assurance of analytical and clinical validity. The goal is to improve safety and consistency of tests that labs create and use for patient care.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 8890 changes status, plus AI-powered summaries and stage predictions.
Sign up free